Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.45 |
| ▸ | MELK | Q14680 | 1/20 | 0.45 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064915 | 1.00 | TSHR (0.52) | TSHRALDH1A1NR4A2JAK2RPS6KA3 | |
| SCHEMBL29620230 | 0.81 | TSHR (0.53) | TSHRALDH1A1CYP3A4HSD17B10HPGD | |
| SCHEMBL4103602 | 0.81 | TSHR (0.53) | TSHRALDH1A1CYP3A4HSD17B10HPGD | |
| SCHEMBL29349435 | 0.81 | JAK2 (0.54) | TSHRALDH1A1JAK2RPS6KA3MELK | |
| SCHEMBL29620231 | 0.81 | TSHR (0.53) | TSHRALDH1A1CYP3A4HSD17B10HPGD | |
| SCHEMBL65699 | 0.81 | JAK2 (0.54) | TSHRALDH1A1JAK2RPS6KA3MELK | |
| SCHEMBL6629381 | 0.79 | TSHR (0.42) | TSHRALDH1A1NR4A2JAK2RPS6KA3 | |
| Hydrochloric Acid SCHEMBL11277860 | 0.78 | JAK2 (0.52) | TSHRALDH1A1JAK2RPS6KA3MELK | |
| SCHEMBL14742902 | 0.78 | ALDH1A1 (0.59) | TSHRALDH1A1JAK2RPS6KA3MELK | |
| SCHEMBL9627127 | 0.78 | JAK2 (0.52) | TSHRALDH1A1JAK2RPS6KA3MELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117839592-A | Preparation device and extraction method of 8-chloro-1-aminonaphthalene | 南京康德祥医药科技有限公司 | 2024-04-09 | — | — | CN | claimed |
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2026-03-05 | — | — | US | disclosed |
| EP-4647424-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-11-12 | — | — | EP | disclosed |
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20240309020-A1 | KRAS G12D INHIBITORS | ARRAY BIOPHARMA INC. | 2024-09-19 | — | — | US | disclosed |
| WO-2024181437-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | 中外製薬株式会社 | 2024-09-06 | — | — | WO | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-113135924-B | Pyrimidine derivatives and their use in medicine | 广东东阳光药业股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| CN-1863784-A | 2-naphthylimino-1,3-thiazine derivative | SHIONOGI & CO (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1659117-A1 | 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2006-05-24 | — | — | EP | disclosed |
| EP-0894799-B1 | INDOLOMORPHINANE DERIVATIVES AND REMEDIES/PREVENTIVES FOR CEREBRAL DISORDERS | TORAY INDUSTRIES (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-6156762-A | Indolomorphinan derivative and agent for curing and preventing cerebral disorder | TORAY INDUSTRIES, INC. (JP) | 2000-12-05 | — | — | US | disclosed |
| EP-0894799-A1 | INDOLOMORPHINANE DERIVATIVES AND REMEDIES/PREVENTIVES FOR CEREBRAL DISORDERS | TORAY INDUSTRIES, INC. (JP) | 1999-02-03 | — | — | EP | disclosed |
| US-4247456-A | Water-insoluble monoazo pyridone dye | CASSELLA AKTIENGESELLSCHAFT (DE) | 1981-01-27 | — | — | US | disclosed |
| US-4237019-A | PROTECTING AQUEOUS MEDIUM SUCH AS WATER BASED PAINTS OR METAL WORKING FLUIDS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1980-12-02 | — | — | US | disclosed |
| EP-0002041-A1 | Processes for synthesizing bisazomethine-bisazo pigments | CIBA-GEIGY AG (CH) | 1979-05-30 | — | — | EP | disclosed |
| US-3957749-A | WATER-INSOLUBLE MONOAZO PYRIDINE DYES | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | TSHR 4213/4885ALDH1A1 1816/4885NR4A2 4644/4885 |
| US-20260062412-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING MYT1 INHIBITORY ACTIVITY | MYT1, NTMT1, MYL6 | TSHR 439/4885ALDH1A1 2880/4885NR4A2 2643/4885 |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | NPM1, OXTR, CYP2S1 | TSHR 440/4885ALDH1A1 1571/4885NR4A2 337/4885 |
| US-20240309020-A1 | KRAS G12D INHIBITORS | KRAS, NRAS, HRAS | TSHR 4393/4885ALDH1A1 2681/4885NR4A2 4022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.